Literature DB >> 21644844

Review of the use of mirtazapine in the treatment of depression.

Sophiya Benjamin1, P Murali Doraiswamy.   

Abstract

INTRODUCTION: Depression is a heterogeneous illness affecting large numbers of patients with far reaching effects on both psychiatric and medical outcomes as well as quality of life. Knowledge about the different treatment modalities used to treat depression is important to all physicians. AREAS COVERED: This article expands on one such treatment option, mirtazapine. The paper examines this medication's medicinal chemistry, pharmacological properties as well as the efficacy of the medication compared to other commonly used antidepressants. EXPERT OPINION: Mirtazapine is a medication unlike other agents used for depression both in its mechanism of action as well as its side effects. Knowing these distinct characteristics will enable physicians to better utilize this agent for the benefit of their patients.
© 2011 Informa UK, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21644844     DOI: 10.1517/14656566.2011.585459

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  11 in total

1.  Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.

Authors:  Alexei Verkhratsky; Vladimir Parpura; Caterina Scuderi; Baoman Li
Journal:  Adv Neurobiol       Date:  2021

2.  PET kinetics of radiolabeled antidepressant, [N-methyl-11C]mirtazapine, in the human brain.

Authors:  Ole L Munk; Donald F Smith
Journal:  EJNMMI Res       Date:  2011-12-15       Impact factor: 3.138

3.  The Antidepressant Mirtazapine Inhibits Hepatic Innate Immune Networks to Attenuate Immune-Mediated Liver Injury in Mice.

Authors:  Wagdi Almishri; Abdel Aziz Shaheen; Keith A Sharkey; Mark G Swain
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

4.  A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome.

Authors:  Alireza Khalilian; Davoud Ahmadimoghaddam; Shiva Saki; Younes Mohammadi; Maryam Mehrpooya
Journal:  Biopsychosoc Med       Date:  2021-02-03

5.  The Antidepressant Mirtazapine Activates Hepatic Macrophages, Facilitating Pathogen Clearance While Limiting Tissue Damage in Mice.

Authors:  Rachelle Paige Davis; Wagdi Almishri; Craig Neal Jenne; Mark Gordon Swain
Journal:  Front Immunol       Date:  2020-11-03       Impact factor: 7.561

6.  Identifying the Subtypes of Major Depressive Disorder Based on Somatic Symptoms: A Longitudinal Study Using Latent Profile Analysis.

Authors:  Xiaohui Wu; Yuncheng Zhu; Zhiguo Wu; Jia Huang; Lan Cao; Yun Wang; Yousong Su; Hongmei Liu; Maosheng Fang; Zhijian Yao; Zuowei Wang; Fan Wang; Yong Wang; Daihui Peng; Jun Chen; Yiru Fang
Journal:  Front Psychiatry       Date:  2022-07-12       Impact factor: 5.435

Review 7.  The molecular pathophysiology of depression and the new therapeutics.

Authors:  Haihua Tian; Zhenyu Hu; Jia Xu; Chuang Wang
Journal:  MedComm (2020)       Date:  2022-07-21

8.  Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study.

Authors:  Hoo Rim Song; Won-Myong Bahk; Young Sup Woo; Jong-Hyun Jeong; Young-Joon Kwon; Jeong Seok Seo; Won Kim; Moon-Doo Kim; Young-Chul Shin; Sang-Yeol Lee; Kyung Joon Min
Journal:  Clin Psychopharmacol Neurosci       Date:  2015-08-31       Impact factor: 2.582

9.  Vertigo/dizziness as a Drugs' adverse reaction.

Authors:  Serafina Chimirri; Rossana Aiello; Carmela Mazzitello; Laura Mumoli; Caterina Palleria; Mariolina Altomonte; Rita Citraro; Giovambattista De Sarro
Journal:  J Pharmacol Pharmacother       Date:  2013-12

10.  Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial.

Authors:  Anne Ostenfeld; Tonny Studsgaard Petersen; Tina Bergmann Futtrup; Jon Trærup Andersen; Andreas Kryger Jensen; Hanne Brix Westergaard; Lars Henning Pedersen; Ellen Christine Leth Løkkegaard
Journal:  BMJ Open       Date:  2020-03-24       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.